Eurofins Discovery

🌟 Celebrating Customer Service Week at Eurofins Discovery in St. Charles! At Eurofins Discovery, serving our clients is at the heart of everything we do. Every day, our dedicated Customer Service and Study Director teams work hand in hand with our customers, driving innovation in drug discovery to tackle global health challenges. Customer Service Week was the perfect opportunity to express our gratitude. A huge thank you to our incredible team for their unwavering commitment and expertise, and to our valued clients for their trust and partnership. Together, we’re making a real impact in the world of drug discovery. Need assistance with your drug discovery outsourcing? Please contact us! https://lnkd.in/g3W8Tfec

As your partner in #biotherapeutics, Eurofins Discovery can deliver differentiated platforms and experienced scientific experts who can accelerate assay development, screening cascades, and drug candidate validation for your biologic program. Access our experts for your programs: ·        Target Validation and Antigen Generation ·        Antibody Discovery ·        Antibody Characterization and Optimization ·        Protein Production ·        Gene & Cell Therapy Discovery Get all the details: https://lnkd.in/dQ6tdZ7Y

One day to go! Attend our webinar, "Unprecedented Fragment-Based Screening Using Spectral Shift for GPCRs" on October 17th! Join our experts, Vanessa Porkolab, Maud Sigoillot, and Alexis Moreno, as they reveal cutting-edge strategies for handling challenging recombinant proteins like GPCRs and the crucial role of biophysics in hit discovery and validation. Key Learning Points: ‣ Explore innovative hit-finding strategies for a wide range of targets, including GPCRs. ‣ Understand the importance of high-quality recombinant proteins in fragment screening. ‣ Increase your hit rate and identify novel starting points with our comprehensive fragment library. ‣ Utilize advanced equipment for effective screening cascades and binding confirmations. ‣ Discover how Spectral Shift, Echo® acoustic droplet ejection, and NanoDSF enhance fragment-based screening, providing robust data and high-affinity hit identification. Don’t miss out on this chance to learn from the experts and discover how to advance your research with our innovative technologies. Register now: https://lnkd.in/gFN6CDKA   #Eurofins #DrugDiscovery #Biophysics #MembraneProteins #GPCR

Custom AI Solutions: We're excited to share how Eurofins DiscoveryAI™ is revolutionizing drug discovery. Our dedicated team works closely with clients to create and implement custom AI solutions that enhance lead optimization projects. By merging advanced machine learning techniques with traditional computational chemistry, we ensure each project leverages the latest technology tailored to your specific needs. Our proprietary, high-quality data fuels AI models, delivering accurate predictions and streamlining the identification of potential drug candidates. Collaboration is key! We adapt our solutions to your evolving goals, driving more innovative and successful outcomes in drug discovery. Ready to explore how we can elevate your research? Let’s connect! https://lnkd.in/gRscfq_x #AI #EurofinsDiscovery #DrugDiscovery

ADME-Tox Webinar: Available on Demand! Missed the recent webinar, CRISPR™ MDCKII Cell Lines Development for Bioavailability and DDI Assessments? Don’t worry! You can still watch it on YouTube: https://lnkd.in/gChbctZb Why watch? - Learn how Eurofins DiscoverX is developing new cell lines with CRISPR technology. - Understand the role and significance of ADME permeability assays. - Explore Drug-Drug Interactions and how we test for them. - Discover how proteomics is reshaping the drug development market. - See Eurofins Discovery’s comprehensive portfolio of assays and expertise for all your ADME-Toxicology needs. Have questions from the webinar or want to learn more about our comprehensive portfolio of ADME-Toxicology solutions? Visit our website! https://lnkd.in/gBeaRwkY #CRISPR #DrugDiscovery #ADME #EurofinsDiscovery

🚀 Exciting News! 🚀 We are thrilled to announce the extension of our groundbreaking collaboration with Dompé for another year! This partnership merges Eurofins Discovery’s unparalleled integrated drug discovery expertise with Dompé’s state-of-the-art AI platform, Exscalate, to accelerate their identification of novel therapeutics. How is Eurofins Discovery progressing drug discovery for companies utilizing internal AI platforms? ✔ Drug Discovery Innovation: Harnessing the power of AI-driven discovery programs to accelerate drug discovery. ✔ Comprehensive Capabilities: Leveraging Eurofins Discovery's extensive resources and cutting-edge technologies to support every phase of drug discovery for small and large molecules. ✔ Proven Track Record: Eurofins Discovery’s history of successful partnerships and impactful discoveries, delivering hits, leads and clinical candidates. ✔ Global Reach: A comprehensive network of laboratories and experts worldwide, ensuring top-tier support and insights. ✔ Efficiency & Cost-Effectiveness: Streamlining processes to bring new therapies to market faster and more affordably. Discover the full story here: https://lnkd.in/gRzFgcKj #DrugDiscovery #AI #Pharmaceuticals #Innovation #Collaboration #EurofinsDiscovery

Mark your calendar for October 17th and join us for a groundbreaking webinar, where the Eurofins Discovery Biophysics team and Eurofins CALIXAR unite their expertise to present “Unprecedented Fragment-Based Screening Using Spectral Shift for GPCRs”! Our experts, Vanessa Porkolab, Maud Sigoillot, and Alexis Moreno will discuss innovative approaches to producing and characterizing challenging recombinant proteins like GPCRs, and how biophysics plays a crucial role in hit finding and confirmation. Unlock new possibilities for your research with: ➊  Fragment-Based Screening (FBS): Discover how fragment-based drug design uncovers novel binding sites on membrane proteins. We used Spectral Shift technology to identify antagonist hit fragments for the human adenosine A2A receptor. ➋ Accelerated Drug Discovery: Learn how our expertise and cutting-edge capabilities in GPCR protein production from Eurofins Calixar and biophysics technologies can speed up your drug discovery processes. ➌  GPCRs and Spectral Shift: Leverage FBS with Spectral Shift technology to find new binding sites on membrane proteins. Don’t miss this opportunity to gain insights from the forefront of GPCR drug discovery and learn how to leverage our cutting-edge technologies for your research. Register today: https://lnkd.in/gFN6CDKA #Eurofins #DrugDiscovery #Biophysics #MembraneProteins #GPCR

📣 Exciting changes are coming to our Fremont, California laboratory in November. Stay tuned for more information in the coming weeks!

Fragment-Based Screening in Drug Discovery Fragment-based screening (FBS) identifies small chemical entities binding to biological targets, offering an alternative to HTS with more sensitive detection and fewer false positives. FBS allows for the detailed analysis of binding affinity, specificity, and stoichiometry. Eurofins Discovery supports your research with: -  Fragment Libraries: Our Fragment ProbeSet features 2.5k+ fragments with 3D, non-planar structures using novel chemical space. -  Screening Capabilities: FBS and HTS streamline your screening cascade. -  Biophysical Platform: Access the latest technologies of SPR, MST-TRIC, Spectral Shift, and TSA. Other services include access to high-quality proteins (Eurofins DiscoverX & Eurofins CALIXAR) and comprehensive scientific and chemistry support, including virtual screening and ADMET prediction. Contact us to explore our full range of Biophysics services: https://lnkd.in/gBqd2kzn Download our fragment-based screening scientific poster: https://lnkd.in/gMR8CzSy Register for the upcoming webinar on fragment-based screening: https://lnkd.in/gFN6CDKA #DrugDiscovery #EurofinsDiscovery

Time is ticking, just 2 more days! Please join us for our webinar, "Accelerating Drug Discovery with Synthetic Chemistry Advances," on October 9th. Take advantage of the opportunity to hear Matthew Horwitz discuss how to accelerate your drug discovery programs with cutting-edge strategies, focusing on small molecules and emerging modalities like proteolysis targeting chimeras (PROTACs®) and antibody-drug conjugates (ADCs). What to expect: - Explore automation, robotics, and parallelization for rapid compound synthesis and effective SAR analysis. - Discover innovative approaches to solve synthetic challenges and optimize lead candidates. Make sure you don’t miss out on how Eurofins Discovery’s new chemical synthesis technologies can fast-track your drug discovery. Register today to gain valuable insights: https://lnkd.in/dZaJcvdr